MétaCan
Menu
← Back to cohort
Record W2018574812 · doi:10.1158/1538-7445.am2012-4405

Abstract 4405: Immune modulation and Treg suppression with metronomic cyclophosphamide enhances the anti-tumor effect of a therapeutic peptide vaccine in a murine model

2012· article· en· W2018574812 on OpenAlexaff
Genevieve Weir, Marianne M. Stanford, Mohan Karkada, Neil L. Berinstein, Marc Mansour

Bibliographic record

VenueCancer Research · 2012
Typearticle
Languageen
FieldImmunology and Microbiology
TopicImmunotherapy and Immune Responses
Canadian institutionsSunnybrook HospitalImmunovaccine (Canada)
Fundersnot available
KeywordsImmune systemCancer vaccineELISPOTImmunologyAdjuvantImmunogenicityVaccinationCancer researchAntigenPeptide vaccineCancerImmunopotentiatorOvarian cancerMedicineT cellBiologyImmunotherapyEpitopeInternal medicine

Abstract

fetched live from OpenAlex

Abstract In order to be optimally effective therapeutic cancer vaccines must be combined with immune modulatory approaches, particularly in advanced cancer where several different pathways of cancer induced immune suppression may be active. We have developed a potent cancer vaccine enhancement formulation named DepoVaxTM (DPX) that is particularly well suited for the delivery of peptide antigens. DPX is a novel vaccine platform comprised of liposomes in oil that is formulated with a TLR adjuvant, universal T-helper peptide and specific tumor peptide antigens. We have shown that DPX generates better immune responses than Montanide based emulsion formulations. A major obstacle to any cancer vaccine, however, is tumor induced immune suppression. Regulatory T cell (Treg) mediated immune suppression is an important mechanism of tumor immune evasion in many types of cancer including ovarian cancer. We sought to determine if combining a DPX-based peptide vaccine approach with immune modulation in the form of Treg suppression could enhance the anti-tumor effect of the vaccine. Metronomic cyclophosphamide (mCPA) treatment has been reported to selectively sustain reduced regulatory T cell numbers and activity. Using a murine tumor model (C3) we tested the benefit of combining mCPA and DPX vaccination for controlling well established subcutaneous solid tumors in vivo. We found that neither mCPA or DPX treatments alone were sufficient to eradicate advanced C3 tumors. However, combining mCPA with DPX vaccination provided effective tumor control. We further characterized the immune response by isolating and phenotyping tumor infiltrating lymphocytes and testing their immunogenicity by IFN-γ ELISPOT assay. Our results indicate that the DPX vaccine can increase the levels of antigen-specific CD8+ T cells and mCPA treatment reduces the CD4+FoxP3+ T regulatory cells. We conclude that immune responses generated by the DPX vaccine were more effective at controlling advanced tumors together with reduced Treg-mediated immune suppression. We have designed and initiated a phase I/II clinical trial to test a DPX vaccine targeting Survivin (DPX-Survivac), in combination with mCPA in ovarian cancer patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4405. doi:1538-7445.AM2012-4405

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.022
GPT teacher head0.332
Teacher spread0.310 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2012
Admission routes1
Has abstractyes

Explore more

Same venueCancer Research→Same topicImmunotherapy and Immune Responses→French-language works237,207→